Derived From Animal Tissue (e.g., Rennin, Etc.) Patents (Class 435/226)
-
Publication number: 20140058790Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.Type: ApplicationFiled: November 30, 2011Publication date: February 27, 2014Applicant: AmideBio LLCInventors: Michael H.B. Stowell, Mikhail Plam
-
Publication number: 20140050716Abstract: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.Type: ApplicationFiled: February 29, 2012Publication date: February 20, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)Inventors: Benoit Polack, Aline Thomas
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20140044773Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: May 7, 2013Publication date: February 13, 2014Inventor: Portola Pharmaceuticals, Inc.
-
Publication number: 20140044701Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: July 30, 2013Publication date: February 13, 2014Inventors: Edwin L. Madison, Christopher Thanos
-
Publication number: 20140044681Abstract: Ctsk is used as a marker to identify, track, and manipulate Ctsk positive cartilaginous stem cells for cartilage repair and regeneration in vitro and in vivo.Type: ApplicationFiled: March 15, 2013Publication date: February 13, 2014Inventor: Rhode Island Hospital
-
Publication number: 20140044796Abstract: The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.Type: ApplicationFiled: February 10, 2012Publication date: February 13, 2014Applicant: OXPROTECT GMBHInventors: Beate Kehrel, Martin Brodde
-
Publication number: 20140030216Abstract: The present invention relates to enhancing, modulating or stimulating the immune response to MMP-2 expressing tumors, including melanoma, and to the modulation and application of immune modulators and MMP-2 peptides for melanoma or other MMP-2 expressing tumor vaccines. The invention provides methods and means to activate an effective response to MMP-2 expressing tumors and modulate the ability of MMP-2 to skew CD4+ T cell responses toward that of TH2 cells, which are less effective mediators of tumor cell clearance than TH1 cells. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating immune responses, particularly to melanoma.Type: ApplicationFiled: June 10, 2013Publication date: January 30, 2014Inventors: Emmanuelle Godefroy, Francine Jotereau, Nina Bhardwaj
-
Patent number: 8609390Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence the mature Fa_RF7182 enzyme having an amino acid sequence of SEQ ID NO: 18. The serine protease is obtainable from Fusarium acuminatum, more preferably from the deposited strain CBS 124084. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2530 comprising the nucleotide sequence SEQ ID NO:12 deposited in Escherichia coli RF7803 under accession number DSM 22208 and plasmid pALK2531 comprising the full-length gene SEQ ID NO: 13 deposited in E. coli RF7879 under accession number DSM 22209, as well as fungal hosts, such as Trichoderm. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.Type: GrantFiled: April 28, 2010Date of Patent: December 17, 2013Assignee: AB Enzymes OyInventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo, George Szakacs
-
Publication number: 20130330319Abstract: The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide or the derivative, wherein the peptide comprises the full-length blood coagulation factor IX, a segment derived from the full-length blood coagulation factor IX by removal of the trypsin domain, the light chain of blood coagulation factor IX, or the EGF1 domain of blood coagulation factor IX, or the EGF3 domain of the endothelial cell locus-1 protein.Type: ApplicationFiled: December 12, 2011Publication date: December 12, 2013Applicant: NIHON UNIVERSITYInventors: Chiaki Hidai, Hisataka Kitano, Atsushi Mamiya
-
Publication number: 20130330808Abstract: The present invention provides process of purification of tissue plasminogen activator (tPA) from a crude mixture or a partially purified mixture containing tPA protein and impurities by using hydrophobic interaction column chromatography, optionally in combination with ion exchange column chromatography.Type: ApplicationFiled: November 15, 2011Publication date: December 12, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sanjay Bandyopadhyay, Sanjeev Kumar Mendiratta, Sushobhan Bandyopadhyay
-
Publication number: 20130330758Abstract: At least at least one embodiment of the present invention relates to a method for using a high pressure-resistant enzyme in a high pressure condition; a method for promoting the activity of the high pressure-resistant enzyme by means of a high pressure treatment; a composition, which contains the high pressure-resistant enzyme, for decomposing proteins under a high pressure condition; a composition, which contains the composition for decomposing proteins, for preparing natural flavoring substances; a container for high pressure treatment, which contains the composition for decomposing proteins; and a method for measuring the activity of the high pressure-resistant enzyme, which comprises a step of decomposing an azocasein solution serving as a substrate by using the high pressure-resistant enzyme treated under a high pressure condition.Type: ApplicationFiled: February 20, 2012Publication date: December 12, 2013Applicant: KOREA FOOD RESEARCH INSTITUTEInventors: Nam-Soo Kim, Chong-Tai Kim, Yong-Jin Cho, Chul-Jin Kim, Jin-Soo Maeng, Soo-Jin Kwon
-
Patent number: 8603795Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence of the mature Fe_RF6318 enzyme having an amino acid sequence of SEQ ID NO: 15. The serine protease is obtainable from Fusarium equiseti, more preferably from the deposited strain CBS 119568. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2521 comprising the nucleotide sequence SEQ ID NO:9 deposited in E. coli RF7664 under accession number DSM 22171 and plasmid pALK2529 comprising the full-length gene SEQ ID NO: 10 deposited in E. coli RF7800 under accession number DSM 22172. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.Type: GrantFiled: April 28, 2010Date of Patent: December 10, 2013Assignee: AB Enzymes OyInventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo
-
Patent number: 8563289Abstract: The present invention relates to methods for producing variants of a parent RP-II protease and the variants having altered properties as compared to the parent RP-II protease.Type: GrantFiled: April 13, 2010Date of Patent: October 22, 2013Assignee: Novozymes A/SInventors: Allan Svendsen, Stefan Minning
-
Publication number: 20130273081Abstract: The present invention relates to pharmaceutical compositions comprising PCSK9 DNA or PCSK9 proteins or PC-SK9 peptides and CpG adjuvant; this composition is used to lower cholesterol levels specifically LDL cholesterol levels.Type: ApplicationFiled: March 25, 2011Publication date: October 17, 2013Inventors: Paolo Monaci, Andrea Carfi
-
Publication number: 20130273634Abstract: A method for the mass production of human coagulation factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation factor VII gene operably linked thereto; b) obtaining a transformed a host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells.Type: ApplicationFiled: October 26, 2011Publication date: October 17, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Chang Hwan Kim, Sung Kap Hong, Byung Sun Lee, Sung Hwan Hong, Se Chang Kwon
-
Patent number: 8557558Abstract: The present specification disclose polynucleotide molecules encoding an enterokinase, yeast expression constructs including a yeast expression vector and a polynucleotide molecules encoding an enterokinase, yeast cells comprising such a yeast expression construct, methods of producing enterokinase using such yeast cells, and method of cleaving or preparing a recombinant polypeptide using an enterokinase produced by such methods.Type: GrantFiled: November 23, 2011Date of Patent: October 15, 2013Assignee: Allergan, Inc.Inventors: Ian Fotheringham, Peter Sheffield
-
Publication number: 20130260439Abstract: The present invention relates to a process for the purification of a protease.Type: ApplicationFiled: June 10, 2013Publication date: October 3, 2013Applicant: Novo Nordisk Health Care AGInventor: Janus Krarup
-
Publication number: 20130243855Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.Type: ApplicationFiled: November 14, 2012Publication date: September 19, 2013Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
-
Publication number: 20130244283Abstract: The present invention relates to a process for the production of a haemostasis protein by continuous perfusion culturing of a cell culture in suspension, said cell culture expressing said haemostasis protein into said culture suspension, wherein the cell culture flows across a filter module, which filter module leads to a harvest port, the filter module having a mesh size of from 0.1 to 2.9 ?m allowing passage across of the haemostasis protein and wherein the flow across the filter module is an alternating tangential flow. The invention also relates to a protein produced by the process of the invention.Type: ApplicationFiled: October 5, 2011Publication date: September 19, 2013Applicant: NOVO NORDISK HEALTH CARE AGInventor: Jarno Robin
-
Patent number: 8507221Abstract: The present invention discloses an improved process for the production of desired recombinant peptides from bacterial cells by using G-CSF as a novel fusion partner for their high level expression in these cells. The invention further provides an expression system comprising the fusion protein wherein the G-CSF is operatively linked to the peptide of interest via an enzymatic or chemical cleavage site which can be used to separate the fusion partner from the said peptide.Type: GrantFiled: September 22, 2008Date of Patent: August 13, 2013Assignee: Cadila Healthcare LimitedInventors: Sanjeev Kumar Mendiretta, Pankaj R. Patel, Sanjay Bandyopadhyay, Vibhor Saraswat, Arun Kumar Singh
-
Publication number: 20130196909Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130196910Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130177541Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: November 3, 2011Publication date: July 11, 2013Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Publication number: 20130177549Abstract: This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods.Type: ApplicationFiled: March 1, 2013Publication date: July 11, 2013Applicant: The Brigham and Women's Hospital, Inc.Inventor: The Brigham and Women's Hospital, Inc.
-
Publication number: 20130171138Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: November 2, 2012Publication date: July 4, 2013Applicant: Syntonix Pharmaceuticals, Inc.Inventor: Syntonix Pharmaceuticals, Inc.
-
Publication number: 20130171156Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.Type: ApplicationFiled: February 28, 2013Publication date: July 4, 2013Applicant: GENERA ISTRAZIVANJA D.O.O.Inventor: Genera Istrazivanja D.O.O.
-
Patent number: 8476054Abstract: A thrombin-like enzyme isolated from Agkistrodon acutus venom, comprising an alpha subunit having the sequence of SEQ ID No. 1 and a beta subunit having the sequence of SEQ ID No. 2, which are linked by seven disulfide bonds, is provided. The hemocoagulase of Agkistrodon acutus in the present invention is a serine proteinase having a molecular weight of 29.3-29.5 kD and an isoelectric point of 5.5, and is able to hydrolyze the alpha chain of human fibrinogen. The invention also provides methods of purifying the thrombin-like enzyme from snake venom, which comprise removing insoluble substance by pretreatment, conducting twice of anion-exchange column chromatography, collecting active eluting peak, dialyzing, ultra-filtrating and desalinating so as to obtain a snake venom thrombin-like enzyme.Type: GrantFiled: March 4, 2009Date of Patent: July 2, 2013Assignee: Konruns Pharmaceutical Co., Ltd.Inventors: Di Sun, Xijuan Wang
-
Publication number: 20130143302Abstract: A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form.Type: ApplicationFiled: July 30, 2010Publication date: June 6, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Gerald Perret, Sami Chtourou, Nicolas Bihoreau
-
Publication number: 20130136732Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicants: Baxter Healthcare S.A., Immune Disease Institute, Inc., Baxter International Inc.Inventors: Baxter Healthcare S.A., Baxter International Inc., Immune Disease Institute, Inc.
-
Publication number: 20130136731Abstract: The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation.Type: ApplicationFiled: August 5, 2011Publication date: May 30, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Neeraj Maheshwari, Girish Sahni
-
Publication number: 20130115204Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.Type: ApplicationFiled: October 24, 2012Publication date: May 9, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Publication number: 20130108610Abstract: The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.Type: ApplicationFiled: October 28, 2011Publication date: May 2, 2013Inventors: James Robert SCHWARTZ, Charles Winston Saunders, Robert Scott Youngquist, Jun Xu
-
Publication number: 20130095555Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.Type: ApplicationFiled: December 21, 2012Publication date: April 18, 2013Applicant: NOVO NORDISK A/SInventor: Novo Nordisk A/S
-
Publication number: 20130096133Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.Type: ApplicationFiled: October 15, 2012Publication date: April 18, 2013Applicant: The Board of Trustees of the University lllinoisInventor: The Board of Trustees of the University of Illinoi
-
Patent number: 8415457Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: GrantFiled: October 30, 2007Date of Patent: April 9, 2013Assignee: Regents of the University of MinnesotaInventor: Gary L. Nelsestuen
-
Publication number: 20130071906Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: ApplicationFiled: September 19, 2012Publication date: March 21, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Patent number: 8389284Abstract: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.Type: GrantFiled: May 25, 2011Date of Patent: March 5, 2013Assignee: Abbott Healthcare Products B.V.Inventors: Willy Deleersnijder, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
-
Patent number: 8383388Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.Type: GrantFiled: June 15, 2007Date of Patent: February 26, 2013Assignee: Catalyst Biosciences, Inc.Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
-
Publication number: 20130045195Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.Type: ApplicationFiled: March 30, 2011Publication date: February 21, 2013Applicant: ALVINE PHARMACEUTICALS, INC.Inventor: Pawan Kumar
-
Publication number: 20130039902Abstract: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.Type: ApplicationFiled: February 10, 2012Publication date: February 14, 2013Applicant: H. Lundbeck A/SInventors: Mariola Sohngen, Wolfgang Sohngen, Wolf-Dieter Schleuning, Robert Medcalf
-
Publication number: 20130034547Abstract: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 ? of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 ? of each other. That sequon is absent from the pre-existing therapeutic polypeptide.Type: ApplicationFiled: August 2, 2012Publication date: February 7, 2013Inventors: Jeffery W. Kelly, Joshua L. Price, Elizabeth K. Culyba, Evan T. Powers
-
Publication number: 20130022983Abstract: Newly identified proteins as markers for the detection of colon and rectal tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.Type: ApplicationFiled: October 26, 2010Publication date: January 24, 2013Applicant: EXTERNAUTICS S.P.A.Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Publication number: 20130017574Abstract: Optimized signal peptide coding sequences for enhanced expression and secretion of protein from a cell and related compositions and methods are described. The optimized signal peptide coding sequence encodes an mRNA that contains at least one hairpin structure immediately downstream of the initiation codon. Methods for obtaining the optimized signal peptide coding sequences and methods for enhanced expression and secretion of proteins using the optimized signal peptide coding sequences are also described.Type: ApplicationFiled: July 16, 2012Publication date: January 17, 2013Applicant: NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY CORP.Inventors: Zhuying WANG, Xiaowu LIU
-
Publication number: 20130017546Abstract: Newly identified proteins as markers for the detection of breast tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.Type: ApplicationFiled: October 26, 2010Publication date: January 17, 2013Applicant: Externautics S.P.A.Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Patent number: 8338568Abstract: A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.Type: GrantFiled: April 30, 2012Date of Patent: December 25, 2012Assignee: Adaerata, Limited PartnershipInventors: Nabil G. Seidah, Jean Davignon, Genevieve Dubuc, Lise Bernier, Michel Tremblay
-
Publication number: 20120308551Abstract: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases.Type: ApplicationFiled: July 2, 2012Publication date: December 6, 2012Inventor: Edwin L. Madison
-
Publication number: 20120308540Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.Type: ApplicationFiled: November 3, 2011Publication date: December 6, 2012Inventors: Edwin L. Madison, Christopher Thanos, Grant Ellsworth Blouse
-
Patent number: 8323913Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: GrantFiled: May 9, 2011Date of Patent: December 4, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz
-
Patent number: 8309341Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group of formula COR4, or R1 represents a group of formula (A): R2 represents a group of formula NR5R6, or R2 represents a nitrogen-containing heterocyclic group, an aryl group or a heteroaryl group, R3 represents a hydrogen atom or an alkyl group, m represents an integer between 1 and 6 inclusive, n represents 0, 1 or 2, their optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating and/or preventing thrombotic events.Type: GrantFiled: June 25, 2010Date of Patent: November 13, 2012Assignees: Les Laboratories Server, L'Institut National des Sciences Appliquées de Rouen, Le Centre National de la Recherche Scientifique, L'Universite de RouenInventors: Philippe Gloanec, Guillaume De Nanteuil, Jean-Gilles Parmentier, Anne-Françoise Guillouzic, Tony Verbeuren, Alain Rupin, Philippe Mennecier, Marie-Odile Vallez, Jean-Charles Quirion, Philippe Jubault, Nicolas Boyer